Agenda
Welcome, Introduction, Polling, and Presurvey Questions
Advances Current Frontline Management of DLBCL
- Case-base discussions
- Current SOC
New Clinical Data and New Approvals
Managing Treatment-Related Adverse Events
On the Horizon: Key Ongoing Trials Spotlight
- frontMIND
- ENGINE
- ESCALADE
- ZUMA-12
Addressing Key Challenges and Future Directions in DLBCL
Closing Remarks and Audience Q&A Session
Events
Date / Time
Event Details
Faculty
Program Director
Jeffrey Abramson, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
Program Director
John M. Burke, MD
Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado
Faculty
Catherine S M Diefenbach
Associate Professor of Medicine
Translational Director Hematology/Director Clinical Lymphoma
Perlmutter Cancer Center
An NCI-designated Comprehensive Cancer Center
NYU Langone Health
New York, New York
Faculty
Alex F. Herrera
Associate Professor
Division of Lymphoma
Department of Hematology and Hematopoietic Cell Transplantation
City of Hope Medical Center
Faculty
Brad S. Kahl, MD
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri
Faculty
Faculty
Matthew J. Matasar, MD, MS
Assistant Member
Lymphoma and Adult Bone Marrow Transplant Services
Memorial Sloan-Kettering Cancer Center
New York, New York
Goal Statement
The goal of this program is to improve patient care by increasing healthcare professional knowledge, competence, and performance in applying new and emerging data on frontline treatment strategies in DLBCL.
Target Audience
This program is intended for hematologists, oncologists, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with DLBCL.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recognize the longstanding unmet medical need and rationale for novel therapies for patients with DLBCL
- Evaluate the potential impact of the risk of disease progression for patients with DLBCL, including the economic and societal burden of failed frontline therapy
- Plan treatment for individual patients with DLBCL, considering available data and expert recommendations
Accreditation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-052-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.